WHO reports hepatitis elimination progress stalled by inequitable access, systemic underfunding, and colonial health legacies
Original framing: “WHO calls for stepped up action to eliminate viral hepatitis” — Global Issues
The WHO’s 2026 report confirms that hepatitis B and C elimination is achievable with existing tools (vaccines, DAAs like sofosbuvir), but only 13% of infected individuals are diagnosed, and treatment coverage is below 5% in low-income countries. Peer-reviewed studies show that patent pooling (e.g., Medicines Patent Pool) could reduce sofosbuvir costs from $84,000 to $68 in generic form, yet pharmaceutical lobbies block this. The '90-90-90' targets (diagnose 90%, treat 90%, cure 90%) are mathematically achievable but politically obstructed by trade agreements like TRIPS. Scientific consensus also links hepatitis to environmental toxins (e.g., aflatoxins in staple foods), yet this is rarely addressed in elimination strategies.
The WHO’s hepatitis elimination narrative frames the crisis as a technical gap solvable through scaled interventions, but the real barriers are structural: patent monopolies that turn treatments into luxury goods, colonial health systems that prioritize extraction over care, and a global governance regime that treats patients as markets rather than rights-holders.
Deep historical patterns—from British sterilization campaigns to CIA hepatitis experiments—reveal how 'global health' has long served geopolitical and corporate interests, while indigenous and marginalized communities have developed holistic, community-driven solutions that remain ignored. The solution lies not in more WHO reports, but in dismantling the intellectual property regimes that sustain pharmaceutical greed, integrating primary care with indigenous knowledge, and centering the voices of those most affected. This requires a trickster’s inversion: treating the WHO’s 'stepped-up action' as the problem, not the solution, and demanding that global health be reclaimed as a commons rather than a commodity. The path forward demands patent pooling, debt cancellation, and indigenous-led care—measures that would not only eliminate hepatitis but also begin to heal the colonial wounds that created the crisis in the first place.